A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1484 participants.
Also called NCT01095666
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,484 participants
- Registry
-
NCT01095666
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China, India, South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01095666. Randomized; quadruple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2013-03 (actual). Results posted on 2017-09-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Dapagliflozin Placebo
- Intervention (Drug)
- Pioglitazone
- Lead sponsor
- AstraZeneca
- Collaborator
- Astra Zeneca, Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01095666- Content hash
ab259c11c84f41a79e67221167cd0337f35f6d0d4da53064c432284dec6bcd92